9-(aminomethyl)-9,10-dihydroanthracene: 5HT2A receptor antagonist; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 10398175 |
| CHEMBL ID | 47482 |
| SCHEMBL ID | 7003538 |
| MeSH ID | M0337980 |
| Synonym |
|---|
| PDSP1_001230 |
| PDSP2_001214 |
| 9,10-dihydroanthracen-9-ylmethanamine |
| 9-aminomethyl-9,10-dihydroanthracene |
| 9,10-dihydroanthracene(dha), 1a |
| bdbm35920 |
| c-(9,10-dihydro-anthracen-9-yl)-methylamine |
| 9-(aminomethyl)-9,10-dihydroanthracene |
| chembl47482 , |
| 22136-76-1 |
| SCHEMBL7003538 |
| amda |
| DTXSID80439253 |
| (9,10-dihydroanthracen-9-yl)methanamine |
| Q4645531 |
| (9,10-dihydroanthracen-9-ylmethyl)amine |
| 9,10-dihydro-9-anthracenemethanamine |
| 9-anthracenemethylamine, 9,10-dihydro- |
| jg5gx32fde , |
| 9-anthracenemethanamine, 9,10-dihydro- |
| unii-jg5gx32fde |
| PD090741 |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Sodium-dependent noradrenaline transporter | Mus musculus (house mouse) | Ki | 10.0000 | 0.0120 | 0.0905 | 0.2900 | AID145696 |
| Prostaglandin G/H synthase 1 | Ovis aries (sheep) | Ki | 0.0200 | 0.0016 | 2.1212 | 9.0000 | AID5444 |
| D(2) dopamine receptor | Homo sapiens (human) | Ki | 10.0000 | 0.0000 | 0.6518 | 10.0000 | AID389737 |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | Ki | 0.0200 | 0.0001 | 0.6017 | 10.0000 | AID5516; AID5531 |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | Ki | 10.0000 | 0.0003 | 1.4656 | 10.0000 | AID389739 |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | Ki | 0.0438 | 0.0000 | 0.3855 | 10.0000 | AID1799359; AID349034; AID389734; AID389735; AID454689; AID5354; AID5355; AID5444 |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | Ki | 0.0430 | 0.0001 | 0.9549 | 10.0000 | AID389736 |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | Ki | 10.0000 | 0.0000 | 0.7048 | 8.1930 | AID389738 |
| 5-hydroxytryptamine receptor 2C | Mus musculus (house mouse) | Ki | 0.0430 | 0.0008 | 0.5032 | 2.8420 | AID5678 |
| Histamine H1 receptor | Homo sapiens (human) | Ki | 0.1380 | 0.0000 | 0.5110 | 10.0000 | AID1799359; AID454690 |
| D(2) dopamine receptor | Mus musculus (house mouse) | Ki | 10.0000 | 0.1120 | 1.6064 | 3.9811 | AID61054 |
| Sodium-dependent serotonin transporter | Mus musculus (house mouse) | Ki | 10.0000 | 0.0004 | 0.5957 | 4.1000 | AID204217 |
| Transporter | Rattus norvegicus (Norway rat) | Ki | 10.0000 | 0.0001 | 0.8667 | 10.0000 | AID145696 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID454690 | Displacement of [3H]chlorphniramine from human histamine H1 receptor expressed in cells | 2009 | Bioorganic & medicinal chemistry, Sep-15, Volume: 17, Issue:18 | Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity. |
| AID454689 | Displacement of [3H]ketanserin from human 5HT2A receptor expressed in cells | 2009 | Bioorganic & medicinal chemistry, Sep-15, Volume: 17, Issue:18 | Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity. |
| AID389734 | Displacement of [3H]ketanserin from 5HT2A receptor expressed in NIH3T3 cells | 2008 | Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21 | Potential modes of interaction of 9-aminomethyl-9,10-dihydroanthracene (AMDA) derivatives with the 5-HT2A receptor: a ligand structure-affinity relationship, receptor mutagenesis and receptor modeling investigation. |
| AID389737 | Displacement of [3H]spiperone from dopamine D2 receptor | 2008 | Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21 | Potential modes of interaction of 9-aminomethyl-9,10-dihydroanthracene (AMDA) derivatives with the 5-HT2A receptor: a ligand structure-affinity relationship, receptor mutagenesis and receptor modeling investigation. |
| AID5678 | Binding affinity to 5-hydroxytryptamine 2C receptor measured using radioligand [3H]Mesulergine in stably transfected NIH3T3 cells | 2001 | Bioorganic & medicinal chemistry letters, Mar-12, Volume: 11, Issue:5 | Influence of chain length and N-alkylation on the selective serotonin receptor ligand 9-(aminomethyl)-9,10-dihydroanthracene. |
| AID5516 | Binding affinity against 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells using [3H]ketanserin | 2001 | Bioorganic & medicinal chemistry letters, Feb-26, Volume: 11, Issue:4 | Exploring the relationship between binding modes of 9-(aminomethyl)-9,10-dihydroanthracene and cyproheptadine analogues at the 5-HT2A serotonin receptor. |
| AID5444 | Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells | 2001 | Bioorganic & medicinal chemistry letters, Mar-12, Volume: 11, Issue:5 | Influence of chain length and N-alkylation on the selective serotonin receptor ligand 9-(aminomethyl)-9,10-dihydroanthracene. |
| AID61054 | Binding affinity to Dopamine receptor D2 using [3H]spiperone as radioligand in stably transfected NIH3T3 cells | 2001 | Bioorganic & medicinal chemistry letters, Mar-12, Volume: 11, Issue:5 | Influence of chain length and N-alkylation on the selective serotonin receptor ligand 9-(aminomethyl)-9,10-dihydroanthracene. |
| AID5354 | Binding affinity was performed using [3H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor (GF-62 cells). | 2002 | Journal of medicinal chemistry, Apr-11, Volume: 45, Issue:8 | Geometry-affinity relationships of the selective serotonin receptor ligand 9-(aminomethyl)-9,10-dihydroanthracene. |
| AID389736 | Displacement of [3H]mesulergine from 5HT2C receptor | 2008 | Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21 | Potential modes of interaction of 9-aminomethyl-9,10-dihydroanthracene (AMDA) derivatives with the 5-HT2A receptor: a ligand structure-affinity relationship, receptor mutagenesis and receptor modeling investigation. |
| AID389735 | Displacement of [3H]ketanserein from 5HT2A receptor F340L mutant expressed in NIH3T3 cells | 2008 | Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21 | Potential modes of interaction of 9-aminomethyl-9,10-dihydroanthracene (AMDA) derivatives with the 5-HT2A receptor: a ligand structure-affinity relationship, receptor mutagenesis and receptor modeling investigation. |
| AID389738 | Displacement of [3H]paroxitine from SERT | 2008 | Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21 | Potential modes of interaction of 9-aminomethyl-9,10-dihydroanthracene (AMDA) derivatives with the 5-HT2A receptor: a ligand structure-affinity relationship, receptor mutagenesis and receptor modeling investigation. |
| AID5355 | Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin | 2004 | Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9 | Structural determinants for high 5-HT(2A) receptor affinity of spiro[9,10-dihydroanthracene]-9,3(')-pyrrolidine (SpAMDA). |
| AID389739 | Displacement of [3H]nisoxitine from NET | 2008 | Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21 | Potential modes of interaction of 9-aminomethyl-9,10-dihydroanthracene (AMDA) derivatives with the 5-HT2A receptor: a ligand structure-affinity relationship, receptor mutagenesis and receptor modeling investigation. |
| AID349034 | Displacement of [3H]ketanserin from human 5HT2A receptor | 2008 | Bioorganic & medicinal chemistry letters, Oct-01, Volume: 18, Issue:19 | Methoxy-substituted 9-aminomethyl-9,10-dihydroanthracene (AMDA) derivatives exhibit differential binding affinities at the 5-HT(2A) receptor. |
| AID204217 | Binding affinity to Serotonin transporter using [3H]-paroxetine as radioligand in stably transfected NIH3T3 cells | 2001 | Bioorganic & medicinal chemistry letters, Mar-12, Volume: 11, Issue:5 | Influence of chain length and N-alkylation on the selective serotonin receptor ligand 9-(aminomethyl)-9,10-dihydroanthracene. |
| AID5531 | Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand | 2003 | Bioorganic & medicinal chemistry letters, Aug-04, Volume: 13, Issue:15 | Ring substituted analogues of 5-aminomethyl-10,11-dihydro-dibenzo[a,d]cycloheptene (AMDH): potential modes of binding to the 5-HT(2A) receptor. |
| AID145696 | Binding affinity to Norepinephrine transporter using [3H]-nisoxatine as radioligand in stably transfected NIH3T3 cells | 2001 | Bioorganic & medicinal chemistry letters, Mar-12, Volume: 11, Issue:5 | Influence of chain length and N-alkylation on the selective serotonin receptor ligand 9-(aminomethyl)-9,10-dihydroanthracene. |
| AID1799359 | Radioligand Binding Assay from Article 10.1016/j.bmc.2009.08.016: \\Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity.\\ | 2009 | Bioorganic & medicinal chemistry, Sep-15, Volume: 17, Issue:18 | Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (8.33) | 18.2507 |
| 2000's | 10 (83.33) | 29.6817 |
| 2010's | 1 (8.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.37) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (8.33%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 11 (91.67%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||